125 related articles for article (PubMed ID: 32347900)
21. The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas.
Valencia K; Erice O; Kostyrko K; Hausmann S; Guruceaga E; Tathireddy A; Flores NM; Sayles LC; Lee AG; Fragoso R; Sun TQ; Vallejo A; Roman M; Entrialgo-Cadierno R; Migueliz I; Razquin N; Fortes P; Lecanda F; Lu J; Ponz-Sarvise M; Chen CZ; Mazur PK; Sweet-Cordero EA; Vicent S
J Clin Invest; 2020 Apr; 130(4):1879-1895. PubMed ID: 31874105
[TBL] [Abstract][Full Text] [Related]
22. The EGFR mutation status affects the relative biological effectiveness of carbon-ion beams in non-small cell lung carcinoma cells.
Amornwichet N; Oike T; Shibata A; Nirodi CS; Ogiwara H; Makino H; Kimura Y; Hirota Y; Isono M; Yoshida Y; Ohno T; Kohno T; Nakano T
Sci Rep; 2015 Jun; 5():11305. PubMed ID: 26065573
[TBL] [Abstract][Full Text] [Related]
23. Nitrilase 1 modulates lung tumor progression in vitro and in vivo.
Wang YA; Sun Y; Le Blanc JM; Solomides C; Zhan T; Lu B
Oncotarget; 2016 Apr; 7(16):21381-92. PubMed ID: 26967383
[TBL] [Abstract][Full Text] [Related]
24. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
25. Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer.
Tang KJ; Constanzo JD; Venkateswaran N; Melegari M; Ilcheva M; Morales JC; Skoulidis F; Heymach JV; Boothman DA; Scaglioni PP
Clin Cancer Res; 2016 Dec; 22(23):5851-5863. PubMed ID: 27220963
[TBL] [Abstract][Full Text] [Related]
26. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
27. Regulation of autophagy, NF-κB signaling, and cell viability by miR-124 in
Mehta AK; Hua K; Whipple W; Nguyen MT; Liu CT; Haybaeck J; Weidhaas J; Settleman J; Singh A
Sci Signal; 2017 Sep; 10(496):. PubMed ID: 28900044
[No Abstract] [Full Text] [Related]
28. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.
Elsum IA; Yates LL; Pearson HB; Phesse TJ; Long F; O'Donoghue R; Ernst M; Cullinane C; Humbert PO
Oncogene; 2014 Nov; 33(48):5523-33. PubMed ID: 24276238
[TBL] [Abstract][Full Text] [Related]
29. DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model.
Weng TY; Yen MC; Huang CT; Hung JJ; Chen YL; Chen WC; Wang CY; Chang JY; Lai MD
Gene Ther; 2014 Oct; 21(10):888-96. PubMed ID: 25077772
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
31. Flavopiridol's effects on metastasis in KRAS mutant lung adenocarcinoma cells.
Dogan Turacli I; Demirtas Korkmaz F; Candar T; Ekmekci A
J Cell Biochem; 2019 Apr; 120(4):5628-5635. PubMed ID: 30317654
[TBL] [Abstract][Full Text] [Related]
32. Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma.
Guibert N; Pradines A; Farella M; Casanova A; Gouin S; Keller L; Favre G; Mazieres J
Lung Cancer; 2016 Oct; 100():1-4. PubMed ID: 27597273
[TBL] [Abstract][Full Text] [Related]
33. Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities.
Serresi M; Siteur B; Hulsman D; Company C; Schmitt MJ; Lieftink C; Morris B; Cesaroni M; Proost N; Beijersbergen RL; van Lohuizen M; Gargiulo G
J Exp Med; 2018 Dec; 215(12):3115-3135. PubMed ID: 30487290
[TBL] [Abstract][Full Text] [Related]
34. Early recognition of lung cancer by integrin targeted imaging in K-ras mouse model.
Ermolayev V; Mohajerani P; Ale A; Sarantopoulos A; Aichler M; Kayser G; Walch A; Ntziachristos V
Int J Cancer; 2015 Sep; 137(5):1107-18. PubMed ID: 25450481
[TBL] [Abstract][Full Text] [Related]
35. LSD1 modulates the non-canonical integrin β3 signaling pathway in non-small cell lung carcinoma cells.
Lim SY; Macheleidt I; Dalvi P; Schäfer SC; Kerick M; Ozretić L; Ortiz-Cuaran S; George J; Merkelbach-Bruse S; Wolf J; Timmermann B; Thomas RK; Schweiger MR; Buettner R; Odenthal M
Sci Rep; 2017 Aug; 7(1):10292. PubMed ID: 28860622
[TBL] [Abstract][Full Text] [Related]
36. Molecular alterations in non-small cell lung carcinomas of the young.
VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
[TBL] [Abstract][Full Text] [Related]
37. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
Mainardi S; Mulero-Sánchez A; Prahallad A; Germano G; Bosma A; Krimpenfort P; Lieftink C; Steinberg JD; de Wit N; Gonçalves-Ribeiro S; Nadal E; Bardelli A; Villanueva A; Bernards R
Nat Med; 2018 Jul; 24(7):961-967. PubMed ID: 29808006
[TBL] [Abstract][Full Text] [Related]
38. Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS.
Caiola E; Brunelli L; Marabese M; Broggini M; Lupi M; Pastorelli R
Oncotarget; 2016 Aug; 7(32):51462-51472. PubMed ID: 27283493
[TBL] [Abstract][Full Text] [Related]
39. [Clinical Analysis of 107 NSCLC Patients Harboring KRAS Mutation].
Zhang Q; Wang J; Li X; Zhang H; Nong J; Qin N; Zhang X; Wu Y; Yang X; Lv J; Zhang S
Zhongguo Fei Ai Za Zhi; 2016 May; 19(5):257-62. PubMed ID: 27215453
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung.
Nemunaitis J; Klemow S; Tong A; Courtney A; Johnston W; Mack M; Taylor W; Solano M; Stone M; Mallams J; Mues G
Am J Clin Oncol; 1998 Apr; 21(2):155-60. PubMed ID: 9537203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
